Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | IL1B | P01584 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27316085 | 0.92 | CRBN (0.54) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL27315977 | 0.92 | CRBN (0.59) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL27316709 | 0.91 | CRBN (0.52) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL27316703 | 0.90 | CRBN (0.53) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL27316708 | 0.90 | CRBN (0.51) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL27316423 | 0.88 | CRBN (0.52) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL27316087 | 0.88 | CRBN (0.60) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL27313577 | 0.87 | CRBN (0.54) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL27316294 | 0.87 | CRBN (0.51) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL27317075 | 0.87 | CRBN (0.52) | CRBNIKZF2IKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |